Table 2.
Randomized controlled trials included in the review (n = 4)
| Study ID | Funding | Country & Setting | Intervention | Comparison | Weeks (sessions) | Total randomised | Mean age of sample | % female in sample | Diagnostics & baseline screening | Primary measures | Secondary measures | Drop-outs | Lost to follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medication | |||||||||||||
| Aliyev and Aliyev 2011 | None | Azerbaijan outpatients (single centre) | Lamotrigine (dose: 25–300 mg/day) | Placebo | 12 | 80 | 37.7 | 0 | CDS | CDS | Improvement | 15 | - |
| Sierra et al. 2003 | None | UK outpatients (single centre) | Lamotrigine (dose: 25–250 mg/day) | Placebo | 12 | 14 | 35.2 | DSM-IV | PSE | DES | 5 | - | |
| PSE | CDS | BDI | |||||||||||
| CDS | |||||||||||||
| Simeon et al. 2004 | NIMH grant | USA outpatients (single centre) | Fluoxetine (dose: 10–60 mg/day) (provided by Eli Lilly) | Placebo | 10 | 54 | 36 | 39 | SCID-D | CGI-I | HRSA | 13 | - |
| Semi-structured clinical interview | DES-DP | HRSD | |||||||||||
| DSS | LSAS | ||||||||||||
| YBOCS | |||||||||||||
| Panic attacks | |||||||||||||
| Psychotherapy | |||||||||||||
| Schoenberg et al. 2012 | Medical Research Council | UK outpatient (single centre) | Electro-dermal biofeedback (8 sessions) | Sham electro-dermal biofeedback | 4 (8) | 32 | 35 | 25 | SCID-D | CDS | - | 2 | - |
| DES | |||||||||||||
| BAI | |||||||||||||
| Pilkington Pilozzo Charitable Trust | BDI | ||||||||||||